First Patient Dosed in Phase 3 Study of Lumryz for Idiopathic Hypersomnia
The study will evaluate the efficacy and safety of Lumryz, an extended-release sodium oxybate, as a once-at-bedtime treatment for idiopathic hypersomnia.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
